Keith Regnante

Insider Reports History

Location
Cambridge, MA
Signature
/s/ Keith Regnante
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Keith Regnante:

Company Role Class Num Shares Value Price $ Report Date Ownership
Keros Therapeutics, Inc. CHIEF FINANCIAL OFFICER Common Stock 39,261 $641,917 $16.35 18 Feb 2026 Direct

Insider Reports Filed by Keith Regnante

Symbol Company Period Transactions Value $ Form Type Role Filing Time
KROS Keros Therapeutics, Inc. 18 Feb 2026 1 -$77,483 4 CHIEF FINANCIAL OFFICER 20 Feb 2026, 16:15
KROS Keros Therapeutics, Inc. 18 Feb 2025 1 $0 4 CHIEF FINANCIAL OFFICER 19 Feb 2025, 16:15
KROS Keros Therapeutics, Inc. 13 Feb 2024 1 $0 4 CHIEF FINANCIAL OFFICER 15 Feb 2024, 20:40
KROS Keros Therapeutics, Inc. 04 Jan 2024 2 -$1,171,600 4/A CHIEF FINANCIAL OFFICER 24 Jan 2025, 16:15
KROS Keros Therapeutics, Inc. 04 Nov 2023 3 -$1,171,600 4 Chief Financial Officer 08 Jan 2024, 16:43
KROS Keros Therapeutics, Inc. 08 Jun 2023 9 -$1,224,239 4 Chief Financial Officer 12 Jun 2023, 16:13
KROS Keros Therapeutics, Inc. 16 Feb 2023 1 $0 4 Chief Financial Officer 17 Feb 2023, 15:14
KROS Keros Therapeutics, Inc. 21 Jan 2022 1 $0 4 Chief Financial Officer 25 Jan 2022, 15:15